单孔钻孔清除慢性硬膜下血肿后活动性骨膜下引流与被动硬膜下引流24小时比较:多中心随机非劣效临床试验SUPERDURA的统计分析计划
SUPERDURA是一项丹麦全国多中心非劣效随机临床试验,比较症状性慢性硬膜下血肿单孔钻孔清除后24小时活动性骨膜下引流与24小时被动硬膜下引流。主要结局为90天死亡率与同侧复发需再手术的复合终点,计划纳入354例(每组177例),非劣效界值为绝对风险增加7%。本文介绍该试验的统计分析计划,在首例受试者纳入前提交。
要点
- 主要结局为90天死亡率与同侧复发需再手术的复合终点。
- 计划纳入354例,每组177例,非劣效界值为绝对风险增加7%。
- 分配序列和区组大小对研究者设盲,由两名统计师进行盲态最终分析。
核心结论
- 所提出的分析计划依据现行指南设计,具有临床重要的主要和次要结局,并在SUPERDURA试验首例受试者纳入前提交,以限制偏倚并提高研究透明度和可重复性。
研究设计与样本
- SUPERDURA是一项丹麦全国多中心非劣效随机临床试验。
- 计划纳入354例受试者,每组177例。
- 主要结局为90天死亡率与90天观察期内同侧复发慢性硬膜下血肿需再手术的复合终点。
- 次要结局为90天简化改良Rankin量表问卷评分、手术相关并发症、入院期间及90天术后严重不良事件和住院时长。
- 探索性结局包括作为有序结局的smRSq评分、主要结局各组分及出院去向。
主要发现
- 研究需纳入354例受试者(每组177例),以在主要复合结局非劣效检验中达到稳定把握度>90%,α为5%,非劣效界值为绝对风险增加7%。
- 分配序列和区组大小对研究者设盲。
- 将在分别完成120例和240例受试者随访后进行安全性和有效性/无效性中期分析。
- 已按照已发表建议创建数据安全监查委员会章程。
- 最终分析将由两名对干预设盲的统计师完成,创建两份摘要,经研究指导委员会批准后揭盲。
关键数值与推荐
- 非劣效界值为绝对风险增加7%。
- 把握度>90%,α为5%。
- 计划纳入354例受试者,每组177例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In Denmark, the current treatment of patients with symptomatic chronic subdural hematoma (CSDH) is single burr hole hematoma evacuation followed by 24-h passive subdural drainage. However, recent studies indicate that 24-h active subperiosteal drainage may be safer and have fewer recurrences. The upcoming SUPERDURA trial will investigate 24-h active subperiosteal drainage versus 24-h passive subdural drainage following single burr-hole evacuation of symptomatic CSDH. This study presents the statistical analysis plan for the SUPERDURA trial. METHODS: SUPERDURA is a national multi-center non-inferiority randomized clinical trial. The primary outcome is a composite of 90-day mortality and ipsilateral recurrent CSDH requiring reoperation within the 90-day observation period. Secondary outcomes are 90-day simplified modified Rankin Scale questionnaire (smRSq) score, complications related to surgery, postoperative serious adverse events during the admission and at 90 days, and length of hospitalization. Exploratory outcomes are smRSq score as an ordinal outcome, each component of the primary outcome, and discharge destination. A total of 354 participants must be included (177 in each intervention group) in the study to achieve a stable power > 90% with an alpha of 5% for non-inferiority testing of the primary composite outcome with a margin at 7% absolute risk increase. The allocation sequence and block sizes are blinded to the investigators. Interim analyses for safety and efficacy/futility will be performed after follow-up is completed for 120 and 240 participants, respectively. A Data Safety Monitoring Committee charter has been created following published recommendations. Final analysis will be done by two statisticians blinded to the intervention, creating two abstracts that are unblinded once approved by the study steering committee. DISCUSSION: The proposed analysis plan is designed in accordance with current guidelines, has clinically important primary and secondary outcomes, and was submitted before the inclusion of the first participant in the SUPERDURA trial to limit bias and increase study transparency and reproducibility. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT06621407.
引用
- Terkelsen JH, Miscov R, Jensen TSR, et al. Active subperiosteal vs. passive subdural 24-h drainage following single burr hole evacuation of chronic subdural hematoma: statistical analysis plan for the multicenter, randomized, non-inferiority clinical trial SUPERDURA. Trials. 2026. PMID: 41546119. doi:10.1186/s13063-026-09434-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。